Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 279

1.

A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.

Tack J, Müller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, Schnekenbuehl S, Dunger-Baldauf C, Rueegg P.

Gut. 2005 Dec;54(12):1707-13. Epub 2005 Jul 14.

PMID:
16020489
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.

Evans BW, Clark WK, Moore DJ, Whorwell PJ.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003960. Review.

PMID:
17943807
[PubMed - indexed for MEDLINE]
3.

Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.

Chey WD, Paré P, Viegas A, Ligozio G, Shetzline MA.

Am J Gastroenterol. 2008 May;103(5):1217-25. doi: 10.1111/j.1572-0241.2008.01808.x.

PMID:
18477346
[PubMed - indexed for MEDLINE]
4.
5.

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.

Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, Gwee KA, Bak YT, Jones J, Wagner A.

Gut. 2003 May;52(5):671-6.

PMID:
12692051
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.

Fock KM, Wagner A; Asia Pacific Gastroenterology Group.

J Gastroenterol Hepatol. 2007 Aug;22(8):1190-8. Epub 2007 May 24.

PMID:
17524039
[PubMed - indexed for MEDLINE]
7.

Tegaserod for the treatment of irritable bowel syndrome.

Evans BW, Clark WK, Moore DJ, Whorwell PJ.

Cochrane Database Syst Rev. 2004;(1):CD003960. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD003960.

PMID:
14974049
[PubMed - indexed for MEDLINE]
8.

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.

Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, Rüegg P, Lefkowitz M.

Aliment Pharmacol Ther. 2002 Nov;16(11):1877-88.

PMID:
12390096
[PubMed - indexed for MEDLINE]
Free Article
9.

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.

Nyhlin H, Bang C, Elsborg L, Silvennoinen J, Holme I, Rüegg P, Jones J, Wagner A.

Scand J Gastroenterol. 2004 Feb;39(2):119-26.

PMID:
15000272
[PubMed - indexed for MEDLINE]
10.

Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.

Wagstaff AJ, Frampton JE, Croom KF.

Drugs. 2003;63(11):1101-20. Review.

PMID:
12749744
[PubMed - indexed for MEDLINE]
11.

Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.

Reilly MC, Barghout V, McBurney CR, Niecko TE.

Aliment Pharmacol Ther. 2005 Sep 1;22(5):373-80.

PMID:
16128674
[PubMed - indexed for MEDLINE]
Free Article
12.

Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.

Harish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P.

J Gastroenterol Hepatol. 2007 Aug;22(8):1183-9.

PMID:
17688659
[PubMed - indexed for MEDLINE]
13.

Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial.

Johanson JF, Wald A, Tougas G, Chey WD, Novick JS, Lembo AJ, Fordham F, Guella M, Nault B.

Clin Gastroenterol Hepatol. 2004 Sep;2(9):796-805.

PMID:
15354280
[PubMed - indexed for MEDLINE]
14.

Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care.

Layer P, Keller J, Mueller-Lissner S, Rüegg P, Loeffler H.

Digestion. 2005;71(4):238-44. Epub 2005 Jul 12.

PMID:
16024929
[PubMed - indexed for MEDLINE]
15.
16.

Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.

Quigley EM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, Diaz C, Shiff SJ, Currie MG, Johnston JM.

Aliment Pharmacol Ther. 2013 Jan;37(1):49-61. doi: 10.1111/apt.12123. Epub 2012 Nov 1.

PMID:
23116208
[PubMed - indexed for MEDLINE]
17.

Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.

Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):435-44.

PMID:
15709995
[PubMed - indexed for MEDLINE]
Free Article
18.

Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.

Tack JF, Miner PB Jr, Fischer L, Harris MS.

Aliment Pharmacol Ther. 2011 Oct;34(8):868-77. doi: 10.1111/j.1365-2036.2011.04818.x. Epub 2011 Aug 24.

PMID:
21883322
[PubMed - indexed for MEDLINE]
19.

Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.

Müller-Lissner S, Holtmann G, Rueegg P, Weidinger G, Löffler H.

Aliment Pharmacol Ther. 2005 Jan 1;21(1):11-20.

PMID:
15644040
[PubMed - indexed for MEDLINE]
Free Article
20.

The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.

Gale JD.

Adv Ther. 2009 May;26(5):519-30. doi: 10.1007/s12325-009-0027-4. Epub 2009 May 14. Review.

PMID:
19444393
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk